LIDDS has successfully completed another preclinical study in mice assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy. Clear anti-tumor effects have been observed in another cancer model in mice where significant decreases in tumor growth was demonstrated. LIDDS has several projects ongoing that focus on assessing the feasibility of using the NanoZolid-technology for local or intratumoral immunotherapy. These studies aim at a local intratumoral delivery of an immune-stimulatory agent. The confirmed anti-tumor effect of an immune-stimulating agent formulated using the NanoZolid-technology in two independent cancer models in mice, will trigger the initiation of follow-on studies. The possibility that local immune- stimulation using the NanoZolid-technology will increase the effects of systemic immunotherapy will be investigated. Results are expected during the next four months. A locally delivered immunotherapy has the potential to act either as a monotherapy or in combination with systemic immunotherapies e.g. checkpoint inhibitors. Successful combination treatments could significantly increase the response rates and efficacy rates of current immunotherapies. As immuno-oncology is the fastest growing area in oncology, reaching a market size over 100 billion USD by 2022, these results should be of great interest to pharmaceutical companies seeking new combination modalities to increase the response rate and efficacy of their immunotherapy drugs.